A Study of Pyridostigmine in Postural Tachycardia Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Droxidopa / Pyridostigmine in Orthostatic Hypotension

NCT01370512

Orthostatic Hypotension

ENROLLING_BY_INVITATION PHASE2

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients

NCT00953914

Diabetes Complications

COMPLETED NA

Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope

NCT04976101

Neurogenic Orthostatic Hypotension

WITHDRAWN NA

The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine

NCT02157545

Muscle Relaxants

WITHDRAWN

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454

Catecholaminergic Polymorphic Ventricular Tachycardia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be done at the outpatient General Clinical Research Center (GCRC) at Charlton 7 and will involve two visits. Visit 1 will take about 3 hours, and Visit 2 will occur 2 days after Visit 1 and will take about 2 hours.

You will be put in one of two groups by chance (as in the flip of a coin). One group will be taking placebo (an inactive substance), the other group 180 mg pyridostigmine in time release formulation. Both placebo and pyridostigmine will look identical and will be taken as one capsule per day for 3 days. Neither you nor the study doctor will know at the time of treatment whether the treatment being given is active or inactive. However, in case of an emergency, this information will be available.

For each of the two visits, the following tests and procedures will be performed:

* When you arrive at the GCRC, you will have a general medical and neurological examination and height and weight measurement.
* Questionnaires. You will be asked to answer a series of questions on your autonomic symptoms (such as rapid heart rate, feeling of tiredness, cold and sweaty hands) at each of your two visits. The questionnaire you will be given during your first visit should take approximately 30 minutes to complete. The questionnaire you will be given during your second visit should take approximately 10 minutes to complete.
* Autonomic Reflex Screen. An autonomic reflex screen will be done during each visit. This consists of the following:

* Quantitative sudomotor axon reflex test (QSART): QSART is a routine clinical test that evaluates the response of the sweat gland to a drug, acetylcholine. One capsule is placed on your forearm and three on your leg and foot. The testing is done by passing a small electrical current, for 5 minutes, to activate the nerves that supply the sweat glands. You will feel a slight burning sensation.
* Cardiovascular recordings: Blood pressure, heart rate, and other cardiovascular measurements will be studied by placing electrodes on the chest and a finger or wrist cuff for continuous blood pressure recordings.
* Valsalva maneuver: This involves blowing very hard into a bugle (like blowing up a balloon) for 15 seconds.
* Head-up tilt: Following a period of rest (at least 5 minutes), you will be tilted up to an angle of not more than 80 degrees and recordings will be made for up to 30 minutes. On Visit 1, one hour after you have taken the study medication, this test will be repeated. This test will be done only once on Visit 2.
* Hormone level measurements: This will be done during each visit. An IV will be inserted into a vein in your arm from which approximately one teaspoon of blood will be drawn while you are lying down and one teaspoon after standing up. This will be repeated only on Visit 1, one hour after the study drug is given. A total of four teaspoons of blood will be drawn on Visit 1 and 2 teaspoons will be drawn on Visit 2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postural Tachycardia Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pyridostigmine

Active study drug

Group Type ACTIVE_COMPARATOR

pyridostigmine

Intervention Type DRUG

one 180 mg capsule per day for 3 days

Placebo

Control

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

one capsule per day for 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pyridostigmine

one 180 mg capsule per day for 3 days

Intervention Type DRUG

Placebo

one capsule per day for 3 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Diagnosis of postural tachycardia syndrome using the following criteria:

* Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
* Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.

Both criteria must be fulfilled.

Exclusion Criteria

* Pregnant or lactating women
* Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
* Hypothyroidism or hyperthyroidism
* Clinically significant coronary artery disease
* Medications that could interfere with autonomic testing
* Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month

Minimum Eligible Age

15 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No